GS-441524 Explained: The Antiviral Behind FIP Recovery

If your vet has just mentioned Feline Infectious Peritonitis (FIP), you are probably reading this with a knot in your stomach and a hundred browser tabs open. Take a breath. The single most important word you need to learn tonight is GS-441524, the antiviral compound that has rewritten the outcome of a disease that was once considered a death sentence for cats.

This guide is written for pawrents in Australia and New Zealand who want a plain-English explanation of what GS-441524 actually is, how it works inside your cat's body, what the real-world success numbers look like, and how it fits into a structured 12-week treatment plan. No hype, no jargon walls, just the information that actually moves the needle on your cat's survival.

A cat resting comfortably at home.

Summary box: what to know in 60 seconds

• What it is: GS-441524 is a nucleoside analogue antiviral that blocks feline coronavirus (FCoV), the virus that mutates into FIP.

• Clinically proven: GS-441524 monotherapy delivered a 92% success rate in the landmark UC Davis study (Pedersen et al., 2019).

• Network experience: Over 100,000 cats have been treated with GS-441524 based protocols since 2019.

• Duration: A standard course is 12 weeks (84 days), under veterinary supervision.

• Forms used in Oceania: Daily subcutaneous injectables or oral capsules, depending on the FIP form and your cat's condition.

What is GS-441524?

GS-441524 is the active antiviral molecule at the heart of modern FIP treatment. Chemically, it is a nucleoside analogue, a man-made building block that resembles one of the natural pieces a virus needs to copy itself. When feline coronavirus tries to replicate inside your cat's cells, it grabs GS-441524 by mistake, and the chain of viral copying stops.

That is the entire reason GS-441524 works. It does not boost the immune system in a vague way and it does not detoxify anything. It quietly sabotages the virus from the inside, day after day, for long enough that your cat's own immune system can clear what is left.

For years, FIP was described as universally fatal. That description belongs in the history books. Thanks to GS-441524, FIP is no longer a death sentence for cats in Australia, New Zealand, or anywhere else with access to proper antivirals.

How GS-441524 works inside your cat

To understand why GS-441524 changed everything, it helps to understand what FIP actually is. Most cats are exposed to feline coronavirus (FCoV) at some point in their lives, usually a mild intestinal infection that resolves on its own. In a smaller percentage of cats, that benign virus mutates into the FIP strain, which then infects immune cells (macrophages) and triggers the devastating inflammatory disease we recognise as FIP.

GS-441524 reaches those infected macrophages, gets phosphorylated inside the cell into its active form, and then jams the viral RNA-dependent RNA polymerase, the enzyme the virus uses to copy its genetic material. With replication blocked, the viral load drops over the treatment course, inflammation calms, and your cat's body gets the breathing room it needs to recover.

This is why consistency matters so much. Skipping doses gives the virus a window to bounce back. The protocol is built around daily dosing for a full 12 weeks because that is what the clinical evidence supports.

The four forms of FIP and why this matters for dosing

FIP does not look the same in every cat. The dose of GS-441524 is matched to the form, because some presentations (especially those affecting the eyes or central nervous system) require the drug to cross more difficult biological barriers.

Wet (effusive) FIP

The classic presentation. Fluid accumulates in the abdomen or chest, creating a swollen belly or laboured breathing. Cats are often lethargic, off their food, and running a stubborn fever that does not respond to antibiotics. Wet FIP usually progresses fastest, which makes early antiviral treatment critical.

Dry (non-effusive) FIP

No dramatic fluid build-up. Instead, granulomas form in organs such as the liver, kidneys, intestines, or lymph nodes. Signs can be vague: chronic weight loss, intermittent fever, jaundice, or a cat that just is not thriving. Dry FIP is harder to diagnose and is sometimes mistaken for other chronic diseases.

Ocular FIP

When FIP settles in the eye, you may notice colour changes in the iris, cloudiness, uneven pupils, or blood in the front chamber of the eye. Ocular involvement requires a higher GS-441524 dose because the drug must reach the inside of the eye in therapeutic concentrations.

Neurological FIP

The most challenging form. Signs include wobbliness, seizures, head tilt, behavioural changes, or hind-leg weakness. The blood-brain barrier blocks many drugs, which is why neurological FIP also requires a higher GS-441524 dose to achieve effective levels in the central nervous system.

A cat can present with more than one form at the same time, and a wet case can shift to dry, ocular, or neurological signs during treatment. This is why veterinary supervision throughout the 12 weeks matters.

The evidence: GS-441524 success rate

The foundational study on GS-441524 was led by Dr Niels Pedersen at the University of California, Davis, and published in 2019. In that trial, GS-441524 delivered a 92% success rate in cats with naturally occurring FIP treated with the injectable antiviral. That is the figure that changed the conversation around FIP from palliative care to active treatment.

Since then, GS-441524 based protocols have been used in over 100,000 cats worldwide. The pattern that emerges from this real-world experience is consistent with the original trial: cats started on treatment early, dosed correctly for their form of FIP, and kept on the full 12-week course have the best chance of long-term recovery and low relapse rates.

GS-441524 is also being studied in dual antiviral combinations. In the Li and Cheah (2025) work on GS-441524 paired with EIDD-1931, the dual oral protocol reported a 78.3% remission rate, offering an additional option where a daily injection is not practical. These are two different protocols with two different stats, and they should not be averaged. Your vet will help you choose the route that suits your cat.

The CureFIP GS-441524 product range in Oceania

CureFIP offers GS-441524 in the forms most commonly used by vets and pawrents across Australia and New Zealand. Prices are in AUD as listed on curefipoceania.com.

GS-441524 Antiviral Injectable, 20 mg/ml, 8 ml, AU$79.00

Available with or without B12. Dosing by FIP type, following the UC Davis protocol (Pedersen et al., PMC6435921):

• Wet: 6 mg/kg

• Dry: 8 mg/kg

• Ocular: 10 mg/kg

• Neurological: 10 mg/kg

Schedule: one subcutaneous injection per day, 7 days a week, for 12 weeks (84 days).

GS-441524 Antiviral Injectables, 30 mg/ml, 8 ml, AU$99.00

A higher concentration option, useful for larger cats or higher-dose forms where smaller injection volumes are easier on the cat. Available with or without B12. Dosing by FIP type:

• Wet: 6 mg/kg

• Dry: 8 mg/kg

• Ocular: 10 mg/kg

• Neurological: 10 mg/kg

Schedule: one subcutaneous injection per day, 7 days a week, for 12 weeks (84 days).

CureFIP Oral Capsules, Dual-Action Formula, AU$139.00

For pawrents who prefer an oral route, the dual-action capsules combine GS-441524 with EIDD-1931 in a single daily capsule. Dosing by body weight:

• Under 2.5 kg: GS-441524 25 mg + EIDD-1931 5 mg

• 2.5 to 5 kg: GS-441524 35 mg + EIDD-1931 8 mg

• Over 5 kg: GS-441524 50 mg + EIDD-1931 12 mg

Schedule: one capsule per day, every day, for a recommended 12 weeks. Note that the dual oral route is positioned for wet and dry FIP. It is generally not recommended once ocular or neurological signs are present, or if your cat cannot eat or defecate normally. In those situations, injectables are the better choice.

What the 12-week treatment journey looks like

Most pawrents find it helpful to think of treatment in three phases.

Week 1, the turning point. Within days of starting GS-441524, many cats show small but meaningful improvements: a flicker of appetite, a lower temperature, a little more interest in their surroundings. This is the moment hope starts to feel real. Stay strict on daily dosing.

Weeks 2 to 8, the climb. Weight returns, fluid resolves in wet cases, eye lesions begin to clear, and neurological signs settle in cats responding well. Bloodwork checkpoints with your vet (typically full blood count and biochemistry) help confirm you are on track.

Weeks 9 to 12, the consolidation. This is the phase where pawrents are most tempted to stop early because the cat looks normal. Do not stop. The remaining weeks are what protect against relapse. Completing the full 84 days is the single biggest predictor of long-term recovery.

After the final dose, your vet will usually recommend an 84-day observation period before declaring sustained remission. Most relapses, when they occur, happen in this window, and they almost always respond to a second course.

Working with your vet in Australia and New Zealand

GS-441524 treatment should always be supervised by a veterinarian. Your vet will confirm the diagnosis, weigh your cat accurately (dosing is per kilogram of current body weight), monitor bloodwork, and adjust the plan if your cat develops new signs during the course. If your regular clinic is unfamiliar with antiviral protocols, ask whether they are willing to consult with an FIP-experienced colleague. More AU and NZ vets are becoming comfortable supervising these protocols every year.

For product details, current pricing, and ordering information in Oceania, visit [curefipoceania.com](https://curefipoceania.com).

FAQ

Is GS-441524 the same as remdesivir?

They are closely related. Remdesivir is a prodrug that the body converts into GS-441524 once inside cells. GS-441524 is the active antiviral molecule itself, which is why it is used directly in feline antiviral protocols.

How quickly will I see GS-441524 working in my cat?

Many cats show early signs of improvement within 24 to 72 hours, especially a drop in fever and a return of appetite. Visible recovery (weight gain, resolution of fluid) usually becomes clear during weeks 2 to 4. The full course remains 12 weeks regardless of how fast your cat improves.

What is the GS-441524 success rate?

In the UC Davis study by Pedersen et al. (2019), GS-441524 monotherapy with injectables produced a 92% success rate. Real-world experience across more than 100,000 cats treated since 2019 has remained consistent with this evidence when protocols are followed correctly.

Can I use the oral capsules instead of injections?

In many wet and dry FIP cases, yes. The CureFIP Oral Capsules Dual-Action Formula provide a daily oral option combining GS-441524 with EIDD-1931. They are generally not recommended once ocular or neurological signs are present, or if your cat is not eating or defecating normally. Discuss the best route with your vet.

What happens if my cat relapses after treatment?

Relapses are most likely in the 84 days after treatment ends. The good news is that relapses generally respond to a second course of GS-441524, often at a higher dose tier (for example, moving up to the ocular or neurological dose if new signs appear). Stay in touch with your vet throughout the observation period.

Is GS-441524 safe for kittens and senior cats?

GS-441524 has been used across a very wide age range, from young kittens to senior cats. Dosing is by current body weight, and your vet will tailor monitoring to your cat's age and overall health. Underlying conditions such as kidney or liver disease should be flagged so your vet can adjust the supportive care plan around the antiviral course.